转移性肢端雀斑样黑色素瘤与其他类型皮肤黑色素瘤一线免疫检查点抑制剂治疗的比较:来自前瞻性皮肤癌登记研究ADOREG的多中心研究
该多中心前瞻性皮肤癌登记研究ADOREG的回顾性分析纳入转移性肢端雀斑样黑色素瘤(ALM)45例和其他类型皮肤黑色素瘤(CM)328例,均接受一线免疫检查点抑制剂(CPI)治疗。ALM患者总生存(OS)有更短趋势(18.1 vs 43.8个月,p=0.10),无进展生存(PFS)无显著差异(7.0 vs 11.5个月,p=0.21),最佳总体缓解(BOR)无显著差异。结论为真实世界队列中ALM一线CPI治疗的生存结局较其他类型CM有更差趋势。
要点
- ALM患者一线CPI治疗后OS有更短趋势(18.1 vs 43.8个月,p=0.10),未达统计学显著。
- ALM与CM患者PFS无显著差异(7.0 vs 11.5个月,p=0.21)。
- ALM与CM患者BOR无显著差异。
核心结论
- 该真实世界队列分析显示,转移性ALM患者一线CPI治疗的生存结局较其他类型皮肤黑色素瘤有更差趋势。
研究设计与样本
- 来自多中心前瞻性皮肤癌登记研究ADOREG的回顾性分析,纳入接受一线CPI治疗的转移性ALM患者45例和CM患者328例。
- 研究终点为最佳总体缓解(BOR)、无进展生存(PFS)和总生存(OS)。
主要发现
- ALM患者较CM患者有显著更高的溃疡性肿瘤率、局部区域转移率,且BRAF突变肿瘤更少。
- 联合CPI治疗在ALM患者中占48.9%,在CM患者中占39.3%,其余患者接受PD-1单药治疗。
- ALM患者OS有更短趋势(18.1 vs 43.8个月,p=0.10),PFS无显著差异(7.0 vs 11.5个月,p=0.21)。
- CM患者中,联合CPI治疗的中位OS未达到,PD-1单药治疗的中位OS为37.8个月(p=0.22)。
- ALM患者中,联合CPI治疗的OS为17.8个月,PD-1单药治疗为26个月(p=0.15)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Melanoma is the main cause of skin cancer-related death. Treatment with immune checkpoint inhibitors (CPI) has improved the prognosis in recent years. However, subtypes of melanoma differ in their response. Acral lentiginous melanoma (ALM) has a worse prognosis compared to cutaneous melanoma other than ALM (CM) and is therefore of particular relevance. AIMS: To evaluate the efficacy of CPI in first-line treatment of patients with advanced ALM compared CM. METHODS: Retrospective analysis of patients with metastatic ALM (n = 45) or CM (n = 328) who received first-line CPI therapy from the multicenter prospective skin cancer registry ADOREG. Study endpoints were best overall response (BOR), progression-free survival (PFS) and overall survival (OS). RESULTS: ALM patients had significantly higher rates of ulcerated tumors, loco regional metastases and fewer BRAF-mutated tumors compared to CM patients. Combined CPI was administered in 48.9 % ALM patients and 39.3 % of CM patients, while the remaining patients received PD-1 monotherapy. OS trended to be shorter in patients with ALM (18.1 vs. 43.8 months, p = 0.10) with no significant differences in PFS (7.0 vs. 11.5 months, p = 0.21). In patients with CM, median OS with combined CPI was not reached, whereas the median OS after PD-1 monotherapy was 37.8 months (p = 0.22). Conversely, in patients with ALM, OS with combined CPI was 17.8 months, compared to 26 months with PD-1 monotherapy (p = 0.15). There were no significant differences in BOR between patients with ALM or CM. CONCLUSION: Analysis of this real-world cohort of patients with metastatic melanoma showed a trend towards poorer survival outcomes upon first-line treatment with CPI in ALM compared to cutaneous melanoma of other subtypes.
引用
- Reinhard S, Utikal JS, Zaremba A, et al. First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG. Eur J Cancer. 2025. PMID: 40121837. doi:10.1016/j.ejca.2025.115356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。